Health Care·Biotechnology·$351.5B
| Metric | Actual | Expected | Surprise |
|---|---|---|---|
| EPS | $1.86 | N/A | +4.91% |
| Revenue | N/A | N/A | N/A |
management commentary, guidance changes, and full analysis available with Pro.
| EPS | $1.86 | N/A | +4.91% |
| Revenue | N/A | N/A | N/A |
Tone: Cautiously Optimistic
Overall, management expressed a cautious optimism about the company's performance. They emphasized their commitment to navigating market challenges.
Management highlighted the continued strength in their core products.
They acknowledged challenges in the market but remain focused on long-term growth.
AbbVie's earnings report showed a positive surprise in EPS, indicating better-than-expected profitability. However, the stock fell by 4.45%, likely due to investor concerns about revenue performance and market challenges. The lack of guidance may have also contributed to the negative stock reaction, as investors often look for future direction from management.
AI-powered briefs, options data, and 20 quarters of history — everything you need before earnings.
No charge today · Auto-bills $8/mo after 7 days · Cancel anytime
VISA INC Class A
Oct 28, 2025